Table 1.
Parameters | Moderate contrast volume (n = 712) | High contrast volume (n = 220) | ||||
---|---|---|---|---|---|---|
Rosuvastatin (n = 357) | Control (n = 355) | P | Rosuvastatin (n = 118) | Control (n = 102) | P | |
Age (years) | 61.8 ± 8.5 | 61.4 ± 8.7 | 0.907 | 61.0 ± 9.2 | 61.5 ± 8.1 | 0.571 |
Men, n (%) | 244 (68.3) | 263 (74.1) | 0.091 | 87 (73.7) | 76 (74.5) | 0.895 |
Risk factors, n (%) | ||||||
Body mass index | 25.5 ± 2.9 | 25.5 ± 2.8 | 0.732 | 25.6 ± 2.9 | 26.1 ± 2.5 | 0.384 |
Current smoker | 114 (31.9) | 122 (34.4) | 0.383 | 41 (34.7) | 43 (42.2) | 0.269 |
Diabetes history, n (%) | ||||||
<5 years | 187 (52.4) | 197 (55.5) | 0.598 | 60 (50.8) | 48 (47.1) | 0.507 |
5–10 years | 71 (19.9) | 71 (20.0) | 27 (22.9) | 20 (19.6) | ||
≥10 years | 99 (27.7) | 87 (24.5) | 31 (26.3) | 34 (33.3) | ||
Hypertension, n (%) | 255 (71.4) | 270 (76.1) | 0.247 | 96 (81.4) | 73 (71.6) | 0.086 |
Prior MI, n (%) | 92 (25.8) | 74 (20.8) | 0.120 | 33 (28.0) | 25 (24.5) | 0.562 |
CAD family history, n (%) | 21 (5.9) | 18 (5.1) | 0.634 | 8 (6.8) | 6 (5.9) | 0.786 |
Hypercholesteremia, n (%) | 28 (7.8) | 21 (5.9) | 0.310 | 7 (5.9) | 2 (2.0) | 0.138 |
Hypertriglyceridemia, n (%) | 35 (9.8) | 30 (8.5) | 0.531 | 13 (11.0) | 8 (7.8) | 0.424 |
Clinical presentation | ||||||
Acute coronary syndromes, n (%) | 304 (85.2) | 300 (84.7) | 0.810 | 102 (86.4) | 87 (85.3) | 0.807 |
SBP, mm Hg | 138.8 ± 20.8 | 140.9 ± 21.2 | 0.561 | 143.3 ± 20.1 | 144.0 ± 26.1 | 0.206 |
DBP, mm Hg | 81.2 ± 13.0 | 81.7 ± 13.7 | 0.861 | 85.0 ± 12.7 | 83.3 ± 14.4 | 0.383 |
NYHA class, n (%) | ||||||
Class I | 292 (81.8) | 290 (81.7) | 0.852 | 101 (85.6) | 86 (84.3) | 0.593 |
Class II | 59 (16.5) | 57 (16.1) | 16 (13.6) | 16 (15.7) | ||
Class III | 6 (1.7) | 8 (2.3) | 1 (0.8) | 0 (0) | ||
Ejection fraction, % | 62.1 ± 8.8 | 62.4 ± 8.0 | 0.095 | 61.9 ± 8.8 | 62.1 ± 8.7 | 0.859 |
Procedural results | ||||||
Diseased vessel number, n (%) | ||||||
0 | 5 (1.4) | 10 (2.8) | 0.254 | 3 (2.5) | 2 (2.0) | 0.880 |
1 | 60 (16.8) | 69 (19.4) | 16 (13.6) | 12 (11.8) | ||
≥2 | 292 (81.8) | 276 (77.7) | 99 (83.9) | 88 (86.3) | ||
PCI, n (%) | 328 (91.9) | 317 (89.3) | 0.238 | 102 (86.4) | 90 (88.2) | 0.690 |
Contrast volume, ml | 212.1 ± 22.6 | 210.7 ± 22.1 | 0.210 | 347.2 ± 86.1 | 343.2 ± 67.3 | 0.336 |
Medications, n (%) | ||||||
ACEI | 241 (67.5) | 223 (62.8) | 0.189 | 88 (74.6) | 69 (67.6) | 0.257 |
ARB | 83 (23.2) | 87 (24.5) | 0.694 | 18 (15.3) | 29 (28.4) | 0.041 |
Antibiotic | 78 (21.8) | 65 (18.3) | 0.239 | 33 (28.0) | 18 (17.6) | 0.070 |
Insulin | 125 (35.0) | 118 (33.2) | 0.618 | 38 (32.2) | 40 (35.71) | 0.574 |
Diuretic | 78 (21.8) | 71 (20.0) | 0.544 | 28 (23.7) | 23 (22.5) | 0.836 |
Calcium antagonist | 136 (38.1) | 137 (38.6) | 0.892 | 55 (46.6) | 46 (45.1) | 0.822 |
β-bloker | 291 (81.5) | 286 (80.6) | 0.747 | 100 (84.7) | 84 (82.4) | 0.632 |
Heparin | 260 (72.8) | 277 (78.0) | 0.107 | 92 (78.0) | 88 (86.3) | 0.111 |
Digitalis | 38 (10.6) | 33 (9.3) | 0.548 | 12 (10.2) | 12 (11.8) | 0.705 |
Hydration | 189 (52.9) | 190 (53.5) | 0.877 | 77 (65.3) | 65 (63.7) | 0.813 |
Data were expressed as n (%) or mean ± SD. MI: Myocardial infarction; CAD: Coronary artery disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; NYHA: New York Heart Association; PCI: Percutanenous coronary intervention; ACEI: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor II blocker; SD: Standard deviation.